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This is true for research, reference, and clinical laboratories. A big
problem facing healthcare worldwide is the increasing number of
multidrug resistant (MDR) Gram-negative bacterial infections. Iden-
tiﬁcation of these resistance mechanisms is extremely important
whether the identiﬁcation is carried out in a research laboratory for a
surveillance study, a reference laboratory for infection control
purposes, or in a clinical laboratory to aid in determining the most
appropriate antibiotic for the infected patient. β-Lactamase produc-
tion is the most prevalent β-lactam resistance mechanism among
Gram-negative pathogens (Hawkey and Jones, 2009). Some of the
more important β-lactamases worldwide contributing to therapeutic
failure include extended-spectrum β-lactamases (ESBLs); carbapene-
mases such as Klebsiella pneumoniae carbapenemases (KPCs), VIM,
IMP, and NDM; and plasmid-mediated AmpC β-lactamases
(pmAmpCs) (Denisuik et al., 2013; Dhillon and Clark, 2012;
Hombauch et al., 2013; Mangold et al., 2011; Rand et al., 2011). In
many cases, the resistance mechanisms responsible for these MDR
organisms are difﬁcult to identify using conventional phenotypic
testing methodology (Denisuik et al., 2013; Rand et al., 2011).
Molecular diagnostic assays using conventional end-point PCR can
take 2–3 hours to complete, followed by gel electrophoresis. Real-
time assays can also take up to 2 hours to complete. This time
constraint can impede laboratories trying to identify organisms
carrying these genes.
A method that could decrease the time for ampliﬁcation and thus
the turn-around time for results would be a useful tool for
laboratories. Therefore, the utility of rapid PCR ampliﬁcation todetect β-lactamase resistance genes in Gram-negative isolates was
evaluated and compared to conventional PCR ampliﬁcation pro-
tocols. Rapid ampliﬁcation methodology requires a higher concen-
tration of magnesium chloride or magnesium sulfate along with
higher primer concentrations in comparison to traditional end-point
PCR protocols. The purpose of this study was 2-fold: 1) to optimize
previously designed primer sets that amplify prevalent β-lactamase
genes using singleplex PCR and 2) to adapt a previously designed
and optimized end-point AmpC multiplex PCR assay for pmAmpC
detection using rapid cycling parameters.
Previously characterized clinical isolates known to carry various
Class A, B, and D β-lactamase genes were used as controls to optimize
singleplex PCR ampliﬁcation conditions. Primer sets used in single-
plex PCRs can serve as a starting point for the detection of key β-
lactamase genes, especially in research laboratories as demonstrated
in this study. We adapted existing primers sets already tested for
speciﬁcity in our laboratory using conventional end-point PCR for use
in a rapid ampliﬁcation protocol. The thermal cycler used in these
experimentswas the Philisa® Thermal Cycler (Streck, Inc., Omaha, NE,
USA). DNA template was obtained by heating bacterial cells to 100 °C
and using 2 μL of supernatant per 50-μL reaction. The Philisa®
Thermal Cycler is capable of using 10–50 μL PCR reactions following
modiﬁcations to the PCR master mix components. PCR reactions were
prepared in thin-walled, elongated tubes crafted for the Philisa®
Thermal Cycler, which allow for efﬁcient heat transfer. Primer sets
previously used on conventional and real-time thermal cyclers were
optimized for rapid cycling conditions and included primers for Class
A (KPC-like, CTX-M Groups 1 and 9, TEM-like, and SHV-like), Class B
(NDM-like, SPM-like, GIM-like, IMP-like, and VIM-like), and Class D
(OXA-1-like, OXA-9, OXA-23-like, OXA-24-like, OXA-40-like, and
OXA-58-like) β-lactamase genes (Table 1). Amplicon sizes ranged
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conditions were electrophoresed, stainedwith ethidium bromide, and
imaged using Kodak computer software. PCR products using primer
sets in Table 1 are shown in Figs. 1 and 2.
Singleplex PCR ampliﬁcations using this methodology were
completed within 16–18 minutes for all primer sets tested using
either Taq or KOD polymerases (Fermentas, ThermoFisher and
Novagen, Millipore, respectively). Programmed conditions for all
singleplexes included an initial denaturation at 95 °C for 15 seconds
followed by 3-step cycling conditions for 30 cycles; 95 °C denaturation
for 5 seconds, annealing for 5 seconds, and 72 °C/70 °C extension forTable 1
Primers used for the detection of common β-lactamase genes using singleplex PCR.
Target Primer
name
Sequence (5′ to 3′) Expected
amplicon size
(bp)
Class A β-lactamases
KPC KPC-F2 GTATCGCCGTCTAGTTCTG 209
KPC-R6 CCTTGAATGAGCTGCACAGTGG
CTX-M
Group 1
CTXM-
1F3
GACGATGTCACTGGCTGAGCTTAGC 499
CTXM-
1R2
AGCCGCCGACGCTAATACA
CTX-M
Group 9
CTXM-
914F
GCTGGAGAAAAGCAGCGGAG 474
CTXM-
914R
GTAAGCTGACGCAACGTCTG
TEM TEM-
prime1F
AGATCAGTTGGGTGCACGAG 750
TEM-
prime2R
TGCTTAATCAGTGAGGCACC
SHV SHV-
prime2F
GGGAAACGGAACTGAATGAG 149
SHV-
prime3R
ATCGTCCACCATCCACTGCA
Class B β-lactamases
NDM NDM1-
F1
GCACACTTCCTATCTCGACATGC 209
NDM1-
R1
CCATACCGCCCATCTTGTCC
VIM VIM1F GGTGTTTGGTCGCATATCGC 504
VIM1R CCATTCAGCCAGATCGGCATC
IMP IMP1F GGAATAGAGTGGCTTAATTC 328
IMP1R CAACCAGTTTTGCTTTACC
SPM SPM-
RTF1
CCCATCCTGTTCCAGCGG 197
SPM-
RTR1
GGCATCTCCCAGATAACC
GIM GIM-
RTF1
GCCCGTGAAGGAAAGCCG 106
GIM-
RTR1
CCTCTGTATGCCCAGCACC
Class D β-lactamases
OXA-9 OXA91F CGTCGCTCACCATATCTCCC 315
OXA91R CCTCTCGTGCTTTAGACCCG
OXA-1
Group
OXA1F TGTGCAACGCAAATGGCAC 579
OXA1B14 CGACCCCAAGTTTCCTGTAAGTG
OXA-23
Group
OXA23-
intF1
CAGAATATGTGCCAGCCTC 546
OXA23-
intR1
GCATTTCTGACCGCATTTCC
OXA-24
Group
OXA24-
intF1
CACCTATGGTAATGCTCTTGC 501
OXA24-
intR1
CAACCTACCTGTGGAGTAACAC
OXA-40
Group
OXA40-
intF1
CACCTATGGTAATGCTCTTGC 491
OXA40-
intR1
GTGGAGTAACACCCATTCC
OXA-58
Group
OXA58-
intF1
GTGGGATGGAAAGCCACG 376
OXA58-
intR1
CACTTGCGGGTCTACAGC
a Sequence used for primer design.15 seconds using either Taq or KOD polymerases, respectively.
Magnesium concentration and annealing temperatures were depen-
dent upon the primer set tested and ranged from 4.0 mmol/L to 5.0
mmol/L and 49 °C to 62 °C, respectively (Table 1). Each PCR reaction
consisted of 1X Taq+KCl PCR buffer, 4.0 mmol/L or 5.0 mmol/L MgCl2,
200 μmol/L dNTP mix, 2 μmol/L of forward and reverse primers, and
1 U of Fermentas Taq (5 U/μL). When using the KOD polymerase, the
PCR reaction included 1X KOD HotStart buffer, 4.0 mmol/L or 5.0
mmol/L MgSO4, 200 μmol/L dNTP mix, 3 μmol/L of forward and
reverse primers, and 1 U of KOD HotStart DNA polymerase (1 U/μL).
The decrease in cycling time reduced the overall time of detectionMgCl2
concentration
(mmol/L)
Additional targets Nucleotide
position
GenBank
accession
numbera
4.0 KPC-2-16 1235-1253 JN048641
1443-1422
5.0 CTX-M-1, 3, 15, 30, 32, 38,
52, 55, 57, 79, 116, 123, 136, 168
1789-1813 AY044436
2287-2269
5.0 CTX-M-9, 14, 19, 24, 27, 65, 93, 98,
104–106, 110–113, 121–123, 125,
126, 129, 130, 134,
1857-1876 AF252622
2330-2311
4.0 Universal 183-202 JX129214
932-913
4.0 Universal 482-501 JN676879
630-611
4.0 NDM-1-4, 6 180-202 JQ734687
388-369
4.0 VIM-1-4,11, 19, 20, 23–25,
27, 28, 31, 33-38
154-173 JN566054
657-637
4.0 IMP-1, 2, 4, 6–8, 10, 15, 19,
22, 25, 26, 32, 37, 38, 40-42
307-326 EU368856
634-616
4.0 SPM-1 2775-2792 AY341249
2971-2954
4.0 GIM-1 1410-1427 AJ620678
1515-1497
4.0 OXA-9 4498-4517 AF034958
4812-4793
4.0 OXA-1, 4, 30, 31 400-418 JN003856
978-956
4.0 OXA-23, 27, 49, 73, 133,
134, 165–171, 225, 239
1451-1469 JN207493
1996-1977
4.0 OXA-24-26, 40,
72, 139, 207
4326-4346 JN207494
4826-4805
4.0 OXA-24-26, 33, 40,
72, 139, 207
192-212 AF509241
682-664
4.0 OXA-58, 96, 156 1813-1830 JQ412186
2188-2171
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Fig. 1. Agarose gel electrophoresis of singleplex PCRs using rapid ampliﬁcation methodology and Taq DNA polymerase. Panel A. Singleplex PCR ampliﬁcations detecting OXA-1 and
OXA-9 templates. Lane 1: GeneRuler 1 kb Plus ladder (Fermentas). Lanes 2, 5, 6, 8: no template controls. Lanes 3 and 4: OXA-1 template. Lane 7: OXA-9 template. Panel B. Singleplex
PCR ampliﬁcation detecting CTX-M-15 and CTX-M-14 templates. Lanes 1 and 10: GeneRuler 1 kb Plus ladder. Lanes 2, 5, 6, and 9: no template controls. Lanes 3 and 4: CTX-M-15
template. Lanes 7 and 8: CTX-M-14 template. Panel C. Singleplex PCR ampliﬁcations detecting VIM, IMP, SPM, and GIM templates. Lanes 1 and 8: GeneRuler 1 kb Plus ladder. Lanes 2
and 7: no template controls. Lanes 3, 4, 5, and 6: VIM-28, IMP-8, SPM, and GIM templates, respectively. Panel D. Singleplex PCR ampliﬁcations detecting OXA-23, OXA-24, OXA-40,
and OXA-58 templates. Lanes 1 and 8: GeneRuler 1 kb Plus ladder. Lanes 2 and 7: no template controls. Lanes 3, 4, 5, 6: OXA-23, OXA-24, OXA-40, and OXA-58, respectively. Agarose
concentrations for all gels was 1.5%.
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decreased the total cost of the singleplex PCRs.
Primer sets previously designed for the detection of blaCMY-2,
blaFOX, blaACT, blaACC, blaMOX, and blaDHA were used in adapting the
ampC multiplex PCR assay for rapid ampliﬁcation end-point PCR
(Table 2) (Perez-Perez and Hanson, 2002). However, the CMY-2
primer set and the forward primer speciﬁc for FOX were redesigned
for optimization of this assay. The CMY-2 primer set was redesigned
to prevent cross hybridization with the chromosomal ampC gene in
Escherichia coli, which had not been observed for this primer set in the
original ampC multiplex PCR assay. The new CMY-2 primer set
produced an amplicon that was similar in size to the original FOX
primer set. Therefore, the forward FOX primer was redesigned to
generate a slightly larger amplicon of 247 bp instead of 190 bp.
Amplicon sizes ranged from 106 bp to 520 bp. E. coli transformants
containing pmAmpC gene fragments served as positive controls. DNA
template was isolated using the DNeasy® Blood and Tissue Kit
(Qiagen, Valencia, CA, USA). Two microliters (~50 ng) of diluted
template was used in a 50-μL reaction.
The optimized ampC multiplex PCR conditions adapted for rapid
PCR ampliﬁcation included an initial denaturation at 95 °C for 15
seconds followed by 3-step cycling for 30 cycles; denaturation at 95 °Cfor 5 seconds, annealing at 65 °C for 10 seconds, and extension at 70 °C
for 15 seconds. A ﬁnal extension step was included at 70 °C for 15
seconds. The extension temperature for the KOD polymerase was
70 °C, while Taq polymerase had an extension temperature of 72 °C
extension. The thermal cycler used for these ampliﬁcations was the
Philisa® Thermal Cycler. The annealing temperature for the ampC
multiplex assay was increased by 1 °C for adaptation on the Philisa®.
Each 50-μL PCR reaction contained 1XKODHotStart buffer, 4.0mmol/L
MgSO4, 0.1mmol/L of each dNTP, 0.5 μL KODHotStart DNApolymerase
(1 U/μL), and 1.1 μmol/LMOXMF/MR; 0.5 μmol/L CMY2MF5/MR2; 0.8
μmol/L DHAMF/MR; and 0.3 μmol/L ACCMF/MR, EBCMF/MR, and FOX
CF2/MRprimers. Each ampliﬁcation reaction shown in Fig. 3 contained
all 6 primer sets and DNA template from their respective AmpC family.
One major ampliﬁed product was shown for each AmpC control.
Ampliﬁcation using rapid cycling parameters was completed in 18
minutes compared to 2.5 hours with end-point PCR ampliﬁcation
protocols. PCR products were visualized as described above.
Rapid ampliﬁcation is an efﬁcient tool that can be used for multiple
applications in research, reference, and clinical laboratories. Here,
we used existing primer pairs for the detection of β-lactamase
genes. Applications already in use in any research, reference, or
diagnostic laboratory could be easily converted for use in rapid
ANDM-1 KPC-2 
500bp
200bp
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700bp
TEM-1 
SHV-12 
200bp
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Fig. 2. Agarose gel electrophoresis of singleplex PCRs for NDM, KPC, TEM, and SHV genes using rapid ampliﬁcation methodology and Taq DNA polymerase. Panel A. Singleplex PCR
ampliﬁcations detecting NDM-1 and KPC-2 templates. Lanes 1 and 10: GeneRuler 1 kb Plus ladder. Lanes 2, 5, 6, 9: no template controls. Lanes 3 and 4: NDM-1 templates. Lanes 7 and
8: KPC-2 templates. Panel B. Singleplex PCR ampliﬁcation detecting TEM-1 template. Lane 1: GeneRuler 1 kb Plus ladder. Lanes 2 and 5: no template controls. Lanes 3 and 4: TEM
template. Panel C. Singleplex PCR detecting SHV-12 template. Lanes 1 and 8: GeneRuler 1 kb Plus ladder. Lanes 2 and 7: no template controls. Lanes 3, 4, 5, 6: SHV-12 template.
Agarose concentrations for all gels was 1.5%.
116 C.N. Geyer, N.D. Hanson / Diagnostic Microbiology and Infectious Disease 77 (2013) 113–117ampliﬁcation protocols. The versatility of using either Taq or a
proofreading enzyme allows for downstream applications such as
subcloning or sequencing of products without re-optimization ofTable 2
Primers used for AmpC multiplex PCR adaptation.
Primer name Sequence (5′ to 3′) Target (s)
MOX MF GCTGCTCAAGGAGCACAGGAT MOX-1-7, CMY-1, 8–11, 19
MOX MR CACATTGACATAGGTGTGGTGC
DHA MF AACTTTCACAGGTGTGCTGGGT DHA-1, 5, 6, 7
DHA MR CCGTACGCATACTGGCTTTGC
ACC MF AACAGCCTCAGCAGCCGGTTA ACC-1, 2, 4
ACC MR TTCGCCGCAATCATCCCTAGC
EBC MF TCGGTAAAGCCGATGTTGCGG ACT-1, 2, 5, 8, 14, 15, 16 MIR-1, 2, 3, 4, 6
EBC MR CTTCCACTGCGGCTGCCAGTT
FOX CF2 GCCGAGGCTTACGGGATCAAG FOX-1-9
FOX MR CAAAGCGCGTAACCGGATTGG
CMY2 MF5 CCGAAGCCTATGGCGTGAAATCC CMY-2, 4, 12, 14–16, 25, 27, 29, 30, 32, 3
38, 39, 42, 44–51, 53–56, 58–68, 71–73,
75–77, 79–81, 84, 87
CMY2 MR2 GCAATGCCCTGCTGGAGCG
a Sequence used for primer design.the protocol. Rapid ampliﬁcation methodology has the potential to
enhance the speed by which laboratories can detect resistance
genes in any microbial organism.Expected amplicon size (bp) Nucleotide position GenBank accession numbera
520 358-378 D13304
877-856
405 1244-1265 Y16410
1648-1628
346 861-881 AJ133121
1206-1186
302 1115-1135 M37839
1416-1396
247 1418-1438 X77455
1664-1644
3, 106 3074-3096 JQ318857
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Fig. 3. Agarose gel electrophoresis of ampC multiplex PCR using rapid ampliﬁcation
methodology and KOD HotStart DNA polymerase. AmpC multiplex PCR showing
ampliﬁcation of 6 E. coli transformant controls and 1 positive clinical isolate. Separation
of amplicons was completed using a 2% agarose gel. Lane 1: GeneRuler 1 kb Plus ladder.
Lanes 2–7 are the E. coli transformant controls arranged in decreasing size: MOX (520
bp), DHA (405 bp), ACC (346 bp), ACT (302 bp), FOX (247 bp), and CMY-2 (106 bp).
Lane 8 represents the DNA from a clinical isolate positive for CMY-2.
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